| 6MNL: reference: Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer., Liu J, Duan Z, Guo W, Zeng L, Wu Y, Chen Y, Tai F, Wang Y, Lin Y, Zhang Q, He Y, Deng J, Stewart RL, Wang C, Lin PC, Ghaffari S, Evers BM, Liu S, Zhou MM, Zhou BP, Shi J, Nat Commun. 2018 Dec 5;9(1):5200. doi: 10.1038/s41467-018-07258-y. PMID: 30518851 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).